Genomics and personalised medicines: partner with the UK to develop new treatments

Overview of UK research infrastructure for genomics technologies, and advantages of investment in the UK's life science sector to support new products.



A summary of the UK’s strengths as a partner for genomics technologies and development of personalised medicines, including information on:

  • research and development expertise
  • clinical research infrastructure
  • routes to product development
  • regulatory approval
Published 2 July 2019